What validated risk‑stratification scoring systems are used for patients with non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Validated Risk Stratification Scoring Systems for NSTEMI

The GRACE Risk Score and TIMI Risk Score for Unstable Angina/NSTEMI are the two well-validated scoring systems recommended for risk stratification in NSTEMI patients, with the GRACE score demonstrating superior predictive accuracy compared to physician judgment alone. 1

Primary Scoring Systems

GRACE Risk Score (2.0)

The GRACE score is the preferred tool for comprehensive risk assessment in NSTEMI patients. It predicts:

  • Target outcomes: In-hospital, 6-month, 1-year, and 3-year mortality or death/MI
  • Variables included:
    • Age
    • Killip class
    • Systolic blood pressure
    • Heart rate
    • ST-segment deviation
    • Cardiac arrest on admission
    • Serum creatinine

The GRACE score has been shown to outperform subjective physician assessment for predicting death or MI in intermediate-risk NSTE-ACS patients 1. When combined with left ventricular ejection fraction (LV-EF) <35%, it provides particularly powerful risk stratification: patients with GRACE score >140 and LV-EF <35% have a 9.2% probability of in-hospital life-threatening ventricular arrhythmias and 23% mortality risk 2.

TIMI Risk Score for Unstable Angina/NSTEMI

The TIMI score offers a simpler bedside calculation tool. It predicts:

  • Target outcome: 14-day all-cause death, MI, or urgent revascularization
  • Variables included (1 point each):
    • Age ≥65 years
    • ≥3 risk factors for CAD
    • Known coronary stenosis ≥50%
    • ST-segment deviation ≥0.5 mm
    • ≥2 anginal events in prior 24 hours
    • Aspirin use in prior 7 days
    • Elevated cardiac biomarkers (CK-MB or troponin)

Event rates increase progressively: 4.7% for score 0-1,8.3% for score 2,13.2% for score 3,19.9% for score 4,26.2% for score 5, and 40.9% for scores 6-7 3.

Clinical Application Algorithm

Risk stratification should proceed as follows:

  1. Calculate both GRACE and TIMI scores at presentation using readily available clinical and laboratory data
  2. Obtain echocardiographic LV-EF assessment - this adds critical prognostic information when combined with GRACE score 2
  3. Stratify patients into risk categories:
    • Very high risk: GRACE >140 + LV-EF <35% (consider intensive monitoring for arrhythmias)
    • High risk: GRACE >140 or TIMI ≥5
    • Intermediate risk: GRACE 109-140 or TIMI 3-4
    • Low risk: GRACE ≤108 or TIMI 0-2

Important Caveats

These scores are NOT diagnostic tools - they stratify risk only in patients with suspected or confirmed ACS 1. Do not use them to rule in or rule out NSTEMI.

Despite their validated predictive accuracy, there is insufficient evidence that routine use of these risk scores translates into reduced cardiovascular events 1. Their primary value lies in:

  • Informing discussions with patients about prognosis
  • Guiding decisions about intensity of monitoring
  • Determining timing of invasive coronary angiography
  • Selecting appropriate antithrombotic therapy intensity

The GRACE score demonstrates superior discrimination compared to TIMI in some validation studies (AUC 0.81 vs 0.72) 4, making it the preferred tool when both are available, particularly for predicting in-hospital mortality and life-threatening arrhythmias 2.

Regional wall motion abnormalities on echocardiography independently predict total occlusion of the culprit artery (OR 4.022), which carries worse long-term outcomes, but this finding is not captured by either GRACE or TIMI scores 5. Consider this additional prognostic marker in your overall assessment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.